Related Experiment Video
Updated: Nov 14, 2025
Detection and Isolation of Circulating Melanoma Cells using Photoacoustic Flowmetry
Published on: November 25, 2011
PD-L1 Detection on Circulating Melanoma Cells
Joseph W Po1,2,3, Yafeng Ma4,5,6, Bavanthi Balakrishnar7
1Centre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia. joseph.po@health.nsw.gov.au.
Abstract:
The advent of personalized medicines targeting cell signaling pathways has radically improved melanoma patient outcomes. More recently, immune-modulating therapies disrupting the PD-1/PD-L1 axis have become a powerful tool in the treatment of a range of melanoma, showing a profound improvement in the overall survival outcomes. However, immune checkpoint inhibitors (ICIs) are associated with considerable toxicities and appear to only be efficacious in a subset of melanoma patients. Therefore, there is an urgent need to identify biomarkers that can determine if patients will or will not respond to ICI therapy. Here, we describe an optimized method for analyzing PD-L1 expression on circulating melanoma cells following immunomagnetic enrichment from patient blood samples.
Insights
Researchers developed a new method to analyze PD-L1 expression on circulating melanoma cells. This could help predict patient response to immune checkpoint inhibitors (ICIs) and improve melanoma treatment.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Personalized medicines targeting cell signaling pathways have improved melanoma outcomes.
- Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are effective but only in a subset of melanoma patients.
- ICIs are associated with significant toxicities, necessitating predictive biomarkers.
Purpose of the Study:
- To develop and optimize a method for analyzing PD-L1 expression on circulating melanoma cells.
- To identify potential biomarkers for predicting response to ICI therapy in melanoma patients.
- To improve patient selection for immunotherapy.
Main Methods:
- Immunomagnetic enrichment of circulating melanoma cells from patient blood samples.
- Optimized analysis of PD-L1 expression on enriched circulating melanoma cells.
- Method validation for reliable biomarker assessment.
Main Results:
- Successfully optimized a method for analyzing PD-L1 expression on circulating melanoma cells.
- Demonstrated the feasibility of using immunomagnetic enrichment for this analysis.
- Established a basis for further investigation into PD-L1 as a predictive biomarker.
Conclusions:
- The developed method allows for the analysis of PD-L1 expression on circulating melanoma cells.
- This approach may aid in identifying patients likely to respond to PD-1/PD-L1 axis inhibitors.
- Further validation is needed to establish clinical utility in melanoma treatment selection.
More Related Videos
12:16Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
Published on: March 13, 2013
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019